A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)
Status:
Completed
Trial end date:
2015-03-31
Target enrollment:
Participant gender:
Summary
This randomized, single-blind, proof-of-concept study will investigate the protective effects
of early treatment with Mircera in participants with chronic kidney disease on renal disease
progression. Participants will be randomly assigned to receive 30 microgram (mcg) Mircera as
subcutaneous injection once monthly or matching placebo. Depending on change of hemoglobin
values, the dose of Mircera can be adjusted to 50 mcg or 75 mcg once monthly. The anticipated
time on study treatment is 24 months.